Atlas Trials

The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.

Clinical trial NCT03619044 · TERMINATED

Trial details

NCT number
NCT03619044
Sponsor
Institut Claudius Regaud
Status
TERMINATED
Phase
Not Applicable
Study type
INTERVENTIONAL
HER2-positive Breast Cancer
Start date
2020-08-28
Primary completion
2021-06-11
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.